Initial Statement of Beneficial Ownership (3)

FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Ogier Walter C	2. Date of Event Requiring Statement (MM/DD/YYYY) 9/14/2020	3. Issuer Name and Ticker or Trading Symbol Novus Therapeutics, Inc. [NVUS]
(Last)        (First)        (Middle) C/O NOVUS THERAPEUTICS, INC., 19900 MACARTHUR BLVD., SUITE 550	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                          _____ 10% Owner _____ Officer (give title below)        _____ Other (specify below)
(Street) IRVINE, CA 92612       (City)              (State)              (Zip)	5. If Amendment, Date Original Filed(MM/DD/YYYY)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	8/31/2027	Common Stock	10415	$0.6855	D
Stock Option (Right to Buy)	(1)	8/31/2027	Series X1 Convertible Preferred Stock (2)	461.664	$685.50	D
Stock Option (Right to Buy)	(1)	1/28/2030	Common Stock	19190	$0.495	D
Stock Option (Right to Buy)	(1)	1/28/2030	Series X1 Convertible Preferred Stock (2)	850.662	$495.00	D
Stock Option (Right to Buy)	(1)	9/7/2030	Common Stock	68791	$0.3808	D
Stock Option (Right to Buy)	(1)	9/7/2030	Series X1 Convertible Preferred Stock (2)	3049.408	$380.80	D

Explanation of Responses:
(1)	The option is fully vested.
(2)	Each share of Series X1 Convertible Preferred Stock will be convertible into 1,000 shares of Common Stock upon receipt of the requisite approval of the stockholders of the Issuer.

Remarks: Ex. 24 - Power of Attorney

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Ogier Walter C C/O NOVUS THERAPEUTICS, INC. 19900 MACARTHUR BLVD., SUITE 550 IRVINE, CA 92612	X

Signatures
/s/ Ryan A. Murr, as attorney-in-fact for Walter Ogier		9/24/2020
**Signature of Reporting Person		Date